Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation

Автор: Babyshkina N.N., Dronova T.A., Gervas P.A., Popova N.O., Dobrodeev A.Yu., Kostromitskiy D.N., Afanasyev S.G., Goldberg V.E., Cherdyntseva N.V.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 5 т.21, 2022 года.

Бесплатный доступ

Aim of the study: a systematic analysis of the modern literature data on the nivolumab monotherapy efficacy in patients with metastatic colorectal cancer (mCRC). Material and Methods. The review summarizes the results of clinical studies of the nivolumab efficacy in patients with mCRC between 2012 and 2022. The current approaches to assessing the tumor response in patients treated with immune checkpoint inhibitors are considered, including response patterns and criteria. Results. Data analysis showed that the use of nivolumab in mCRC patients had significant clinical benefits. Nivolumab monotherapy was shown to improve survival in patients with high microsatellite instability (MSi) or deficiencies in mismatch repair (dMMR) that progressed during standard chemotherapy. Numerous clinical studies indicate the atypical response to nivolumab. Traditional response criteria, such as RECiST do not always adequately assess the therapeutic efficacy of nivolumab in patients with mCRC. conclusion. To improve the efficacy of mCRC treatment, standardized approaches based on the proposed specific criteria for response to immunotherapy, including immune related RECiST, immune RECiST, and immune-modified RECiST must be developed.

Еще

Metastatic colorectal cancer, nivolumab, atypical response patterns

Короткий адрес: https://sciup.org/140296671

IDR: 140296671   |   DOI: 10.21294/1814-4861-2022-21-5-135-141

Список литературы Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation

  • Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-49. https://doi.org/10.3322/caac.21660.
  • Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shakhzadovoi. M., 2021. 252 s.
  • Aparicio J., Esposito F., Serrano S., Falco E., Escudero P., RuizCasado A., Manzano H. Fernandez-Montes A. Metastatic colorectal cancer. First line therapy for unresectable disease. J Clin Med. 2020; 9(12): 3889. https://doi.org/10.3390/jcm9123889.
  • Odintsova I.N., Cheremisina O.V., Pisareva L.F., Spivakova I.O., Vusik M.V. Epidemiologiya kolorektal'nogo raka v Tomskoi oblasti. Sibirskii onkologicheskii zhurnal. 2017; 16(4): 89-95. https://doi.org/10.21294/1814-4861-2017-16-4-89-95.
  • Benson A.B., Venook A.P., Al-Hawary M.M., Arain M.A., Chen Y.J., Ciombor K.K., Cohen S., Cooper H.S., Deming D., Farkas L., GarridoLaguna I., Grem J.L., Gunn A., Hecht J.R., Hoffe S., Hubbard J., Hunt S., Johung K.L., Kirilcuk N., Krishnamurthi S., Messersmith W.A., Meyerhardt J., Miller E.D., Mulcahy M.F., Nurkin S., Overman M.J., Parikh A., Patel H., Pedersen K., Saltz L., Schneider C., Shibata D., Skibber J.M., Sofocleous C.T., Stoffel E.M., Stotsky-Himelfarb E., Willett C.G., Gregory K.M., Gurski L.A. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2002; 19(3): 329-59. https://doi.org/10.6004/jnccn.2021.0012.
  • Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J.H., Aderka D., Aranda Aguilar E., Bardelli A., Benson A., Bodoky G., Ciardiello F., D'Hoore A., Diaz-Rubio E., Douillard J.Y., Ducreux M., Falcone A., Grothey A., Gruenberger T., Haustermans K., Heinemann V., Hoff P., Kohne C.H., Labianca R., Laurent-Puig P., Ma B., Maughan T., Muro K., Normanno N., Osterlund P., Oyen W.J., Papamichael D., Pentheroudakis G., Pfeiffer P., Price T.J., Punt C., Ricke J., Roth A., Salazar R., Scheithauer W., Schmoll H.J., Tabernero J., Taieb J., Tejpar S., Wasan H., Yoshino T., Zaanan A., Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8): 1386-1422. https://doi.org/10.1093/annonc/mdw235.
  • Zlokachestvennye novoobrazovaniya obodochnoi kishki i rektosigmoidnogo otdela. MKB 10: C18, C19. 2020.
  • Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., Brahmer J.R., Lawrence D.P., Atkins M.B., Powderly J.D., Leming P.D., Lipson E.J., Puzanov I., Smith D.C., Taube J.M., Wigginton J.M., Kollia G.D., Gupta A., Pardoll D.M., Sosman J.A., Hodi F.S. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32(10): 1020-30. https://doi.org/10.1200/JCO.2013.53.0105.
  • Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., Tykodi S.S., Sosman J.A., Procopio G., Plimack E.R., Castellano D., Choueiri T.K., Gurney H., Donskov F., Bono P., Wagstaff J., Gauler T.C., Ueda T., Tomita Y., Schutz F.A., Kollmannsberger C., Larkin J., Ravaud A., Simon J.S., Xu L.A., Waxman I.M., Sharma P. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373(19): 1803-13. https://doi.org/10.1056/NEJMoa1510665.
  • Bristol-Myers Squibb (2014) Phase 2 objective response rate and survival data for Opdivo (nivolumab) in heavily pre-treated advanced squamous cell non-small cell lung cancer. To be presented at the 2014 Chicago multidisciplinary symposium on thoracic oncology [Internet]. Bristol-Myers Squibb Company; 2014. URL: https://news.bms.com/news/details/2014/Phase-2-Objective-Response-Rate-and-Survival-Data-forOpdivo-nivolumab-in-Heavily-Pre-treated-Advanced-Squamous-CellNon-Small-Cell-Lung-Cancer-to-be-Presented-at-the-2014-ChicagoMultidisciplinary-Symposium-on-Thoracic-Oncology/default.aspx. [cited 2022 June 25].
  • Overman M.J., McDermott R., Leach J.L., Lonardi S., Lenz H.J., Morse M.A., Desai J., Hill A., Axelson M., Moss R.A., Goldberg M.V., Cao Z.A., Ledeine J.M., Maglinte G.A., Kopetz S., Andre T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18(9): 1182-91. https://doi.org/10.1016/S1470-2045(17)30422-9.
  • Morris V.K., Salem M.E., Nimeiri H., Iqbal S., Singh P., Ciombor K., Polite B., Deming D., Chan E., Wade J.L., Xiao L., Bekaii-Saab T., Vence L., Blando J., Mahvash A., Foo W.C., Ohaji C., Pasia M., Bland G., Ohinata A., Rogers J., Mehdizadeh A., Banks K., Lanman R., Wolff R.A., Streicher H., Allison J., Sharma P., Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(4): 446-53. https://doi.org/10.1016/S1470-2045-(17)30104-3.
  • Yamamoto N., Nokihara H., Yamada Y., Shibata T., Tamura Y., Seki Y., Honda K., Tanabe Y., Wakui H., Tamura T. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs. 2017; 35(2): 207-16. https://doi.org/10.1007/s10637-016-0411-2.
  • Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., Gilson M.M., Wang C., Selby M., Taube J.M., Anders R., Chen L., Korman A.J., Pardoll D.M., Lowy I., Topalian S.L. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19): 3167-75. https://doi.org/10.1200/JCO.2009.26.7609.
  • Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002; 99(19): 12293-7. https://doi.org/10.1073/pnas.192461099.
  • FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer [Internet]. U.S. Food and Drug Administration; 2017. URL: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm. [cited 2022 Jun 29].
  • Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26): 2455-65. https://doi.org/10.1056/NEJMoa1200694.
  • Mollica V., Di Nunno V., Corcioni B., Fiorentino M., Nobili E., Schiavina R., Golfieri R., Brunocilla E., Ardizzoni A., Massari F. A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. Anticancer Drugs. 2018; 29(9): 911-3. https://doi.org/10.1097/CAD.0000000000000663.
  • Namikawa T., Ishida N., Tsuda S., Fujisawa K., Munekage E., Iwabu J., Munekage M., Uemura S., Tsujii S., Maeda H., Kitagawa H., Kobayashi M., Hanazaki K. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surg Case Rep. 2018; 4(1): 71. https://doi.org/10.1186/s40792-018-0479-3.
  • Borcoman E., Kanjanapan Y., Champiat S., Kato S., Servois V., Kurzrock R., Goel S., Bedard P., Tourneau C.Le. Novel patterns of response under immunotherapy. Ann Oncol. 2019; 30(3): 385-96. https://doi.org/10.1093/annonc/mdz003.
  • Tazdait M., Mezquita L., Lahmar J., Ferrara R., Bidault F., Ammari S., Balleyguier C., Planchard D., Gazzah A., Soria G.C., Marabelle A., Besse B., Caramella C. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018; 88: 38-47. https://doi.org/10.1016/j.ejca.2017.10.017.
  • Lipson E.J., Sharfman W.H., Drake C.G., Wollner I., Taube J.M., Anders R.A., Xu H., Yao S., Pons A., Chen L., Pardoll D.M., Brahmer J.R., Topalian S.L. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013; 19(2): 462-8. https://doi.org/10.1158/1078-0432.CCR-12-2625.
  • Ruiz-Banobre J., Anido U., Abdulkader I., Antunez-Lopez J., LopezLopez R., Garcia-Gonzalez J. Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report. Front Oncol. 2016; 6: 250. https://doi.org/10.3389/fonc.2016.00250.
  • Locati L.D., Serafini M.S., Carenzo A., Canevari S., Perrone F., Orlandi E., Delbue S., Cavalieri S., Berzeri G., Pichiecchio A., Licitra L.F., Marchioni E., De Cecco L. Complete response to nivolumab in recurrent/metastatic HPV-positive head and neck squamous cell carcinoma patient after progressive multifocal leukoencephalopathy: a case report. Front Oncol. 2022; 11: 799453. https://doi.org/10.3389/fonc.2021.799453.
  • Oprea A., Benas A., Havasi A., Gorzo A. Long term administration of nivolumab for metastatic melanoma: a case report. Cureus. 2022; 14(6). https://doi.org/10.7759/cureus.26359.
  • Wolchok J.D., Hamid O., Ribas A., Robert C., Kefford R., Hwu W-J. Weber J.S., Joshua A.M., Gangadhar T.C., Dronca R.S., Daud A., Patnaik A., Joseph R.W., Zarour M.H., Li N.X., Xue D., Ebbinghaus S., Kang S.P., Perrone A.M., Hodi F.S. A typical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. J Clin Oncol. 2015; 33(15): 3000. https://doi.org/10.1200/jco.2015.33.15_suppl.3000.
  • Ferris R.L., Blumenschein G.Jr., Fayette J., Guigay J., Colevas A.D., Licitra L., Harrington K., Kasper S., Vokes E.E., Even C., Worden F., Saba N.F., Iglesias Docampo L.C., Haddad R., Rordorf T., Kiyota N., Tahara M., Monga M., Lynch M., Geese W.J., Kopit J., Shaw J.W., Gillison M.L. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016; 375(19): 1856-67. https://doi.org/10.1056/NEJMoa1602252.
  • Parseghian C.M., Patnana M., Bhosale P., Hess K.R., Shih Y.T., Kim B., Kopetz S., Overman M.J., Varadhachary G.R., Javle M., Naing A., Piha-Paul S., Hong D., Le H., Subbiah V., Pant S. Evaluating for pseudoprogression in colorectal and pancreatic tumors treated with immunotherapy. J Immunother. 2018; 41(6): 284-91. https://doi.org/10.1097/CJI.0000000000000222.
  • Chae Y.K., Wang S., Nimeiri H., Kalyan A., Giles F.J. Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. Oncotarget. 2017; 8(34): 57889-97. https://doi.org/10.18632/oncotarget.18361.
  • Colle R., Radzik A., Cohen R., Pellat A., Lopez-Tabada D., Cachanado M., Duval A., Svrcek M., Menu Y., Andre T. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer. 2021; 144: 9-16. https://doi.org/10.1016/j.ejca.2020.11.009.
  • Schuler A., Omlin A., Husarik D.B., Denecke B., Rothermundt C. Hyper- or pseudoprogression? A case report of MSI-high metastatic colorectal cancer. Ann Clin Case Rep. 2021; 6.
  • Guarini C., Todisco A., Tucci M., Porta C., Mannavola F. Massive hyper-progression during anti-PD-1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review. Precis Cancer Med. 2021; 4: 30. https://doi.org/10.21037/pcm-21-10.
  • Wang Z., Liu C., Bai Y., Zhao X., Cui L., Peng Z., Zhang X., Wang X., Zhao Z., Li J., Shen L. Redefine hyperprogressive disease during treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer. Front. Oncol. 2021; 11: 761110. https://doi.org/10.3389/fonc.2021.761110.
  • Chan K.H., Lakkasani S., Ramahi A., Shaaban H.S. Hyperprogressive disease in an advanced stage colon cancer patient on pembrolizumab: a case report. Cureus. 2020; 12(4). https://doi.org/10.7759/cureus.7764.
  • Zhou W., Zhou Y., Yi C., Shu X., Wei G., Chen X., Shen X., Qiu M. Case report: immune and genomic characteristics associated with hyperprogression in a patient with metastatic deficient mismatch repair gastrointestinal cancer treated with anti-PD-1 antibody. Front. Immunol. 2021; 12: 749204. https://doi.org/10.3389/fimmu.2021.749204.
  • Napolitano M., Trudu L., Bertolini F. Unexpected response to nivolumab in a “Fast Progressor” head and neck cancer patient. Case Rep Oncol. 2019; 12(3): 709-14. https://doi.org/10.1159/000502858.
  • Tozuka T., Kitazono S., Sakamoto H., Yoshida H., Amino Y., Uematsu S., Yoshizawa T., Hasegawa T., Uchibori K., Yanagitani N., Horiike A., Horai T., Seike M., Gemma M., Nishio M. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. BMC Cancer. 2020; 20(1): 207. https://doi.org/10.1186/s12885-020-6704-z.
  • Humbert O., Cadour N., Paquet M., Schiappa R., Poudenx M., Chardin D., Borchiellini D., Benisvy D., Ouvrier M.J., Zwarthoed C., Schiazza A., Ilie M., Ghalloussi H., Koulibaly P.M., Darcourt J., Otto J. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020; 47(5): 1158-67. https://doi.org/10.1007/s00259-019-04573-4.
  • de Velasco G., Krajewski K.M., Albiges L., Awad M.M., Bellmunt J., Hodi F.S., Choueiri T.K. Radiologic heterogeneity in responses to antiPD-1/PD-L1 therapy in metastatic renal cell carcinoma. Cancer Immunol Res. 2016; 4(1): 12-7. https://doi.org/10.1158/2326-6066.CIR-15-0197.
  • Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbé C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R., Hodi F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23): 7412-20. https://doi.org/10.1158/1078-0432.CCR-09-1624.
  • Nishino M., Giobbie-Hurder A., Gargano M., Suda M., Ramaiya N.H., Hodi F.S. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013; 19(14): 3936-43. https://doi.org/10.1158/1078-0432.CCR-13-0895.
  • Seymour L., Bogaerts J., Perrone A., Ford R., Schwartz L.H., Mandrekar S., Lin N.U., Litière S., Dancey J., Chen A., Hodi F.S., Therasse P., Hoekstra O.S., Shankar L.K., Wolchok J.D., Ballinger M., Caramella C., de Vries E.G.E.; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18(3): 143-52. https://doi.org/10.1016/S1470-2045(17)30074-8. Erratum in: Lancet Oncol. 2019; 20(5): 242.
  • Hodi F.S., Ballinger M., Lyons B., Soria J.C., Nishino M., Tabernero J., Powles T., Smith D., Hoos A., McKenna C., Beyer U., Rhee I., Fine G., Winslow N., Chen D.S., Wolchok J.D. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018; 36(9): 850-8. https://doi.org/10.1200/JCO.2017.75.1644
Еще
Статья научная
SciUp 2024 © 2024 ©